We identified COL10A1 as a marker of high-risk BCC subtypes, particularly in sclerosing/infiltrative and basosquamous subtypes. This could serve as a prognostic biomarker and a target for personalized treatment.
This study investigates the use of cfDNA sequencing to monitor tumor dynamics in patients undergoing high-dose radiotherapy, revealing correlations between genetic alterations and clinical outcomes.
We developed machine learning models, PRIDICT2.0 and ePRIDICT, to predict prime editing efficiency, offering a robust tool for optimizing genome editing strategies across diverse chromatin contexts.
Method development for the analysis of cell-free DNA (cfDNA) sequencing data is impeded by limited data sharing due to the strict control of sensitive genomic data. An existing solution for facilitating data sharing removes nucleotide-level …
We investigated Talimogene laherparepvec (T-VEC) and its effect on the clinical, histological, single-cell transcriptomic and immune repertoire level using repeated fine-needle aspirates (FNAs) of injected and noninjected lesions in primary cutaneous B-cell lymphoma (pCBCL).
An introduction to long-read sequencing.
Cancer on the cell level.
Novel computational method for drug-drug interaction predictions which are an important consideration for patient treatment.
We are currently looking for Master’s students in the field of Bioinformatics for the topic of
Nucleosome footprints in cell-free DNA sequencing data Cell-free DNA (cfDNA) is released by dying cells into the surrounding tissues and also to the bloodstream. As nucleosomes protect DNA from degradation, plasma cfDNA carries information about the nucleosome organization in the cells of origin. Different characteristics of cfDNA are increasingly being used in the diagnostics of genetic diseases and the monitoring of cancer.